AM-906.

AM-906 is a classical cannabinoid of the AM series: a hexahydrocannabinol skeleton bearing a hydroxymethyl at position 9, and a hept-1-enyl side chain of cis geometry at position 3, whose double bond blocks rotation around the C1'-C2' bond. This constraint was the aim of the study by Busch-Petersen et al. (1996), which measured what the geometry of the side chain imposes on recognition by the receptors. In this series, the cis analogue showed the highest affinity for CB1, with a Ki of 0.89 nM in displacement of [3H]CP-55940 on rat brain microsomes, and the widest separation between CB1 and CB2, the affinity for CB2 being 9.5 nM on a mouse spleen preparation (ChEMBL). Its trans isomer, AM-905, binds less strongly to CB1 (1.2 nM). The limit of this finding must be stated clearly: only binding was measured. No functional assay was found for this molecule, so that its efficacy, i.e. whether it is a full or partial agonist, is not established. No action at TRPV1, GPR55, PPARγ or 5-HT1A is reported, and human, pharmacokinetic, metabolism and toxicology data are entirely lacking.

Source

An entirely synthetic molecule, absent from cannabis as from any living organism. It was designed as a pharmacology tool (Busch-Petersen 1996). Its name nevertheless circulates online: a forum-crawling robot, active from 14 November 2017 to 31 May 2019, picked it up among 1,103 synthetic cannabinoids mentioned on these platforms, 863 of which were in neither the UNODC nor the EMCDDA databases; AM-906 is listed neither on the UNODC list (13 June 2019) nor in the EMCDDA database (1 April 2019) (Zangani 2020). No seizure and no use in a consumer product is reported in the sources consulted.

No known biosynthetic pathway: the molecule is produced by no living organism. It is obtained by chemical synthesis and described here only by its class, that of the classical cannabinoids of the β-11-hydroxyhexahydrocannabinol type with an unsaturated side chain.

European Union

No Union text targets this molecule: it is not among the substances named in the annex of Framework Decision 2004/757/JHA as supplemented by Directives (EU) 2017/2103, 2019/369, 2020/1687, 2021/802, 2022/1326 and 2025/2062, nor in Schedule II of the 1971 Convention (Green List of the International Narcotics Control Board, 35th edition, 2024). The survey by Zangani et al. (2020), which compares the EMCDDA database as of 1 April 2019 and the UNODC list as of 13 June 2019 with forum mentions, places it outside both directories. Control therefore rests with each Member State, several of which have adopted generic clauses covering cannabinoid skeletons, as France has.

France

AM-906 is named in no French text: the consolidated list of ANSM (updated 16 February 2026) does not cite it, whereas HU-210 and HU-243, built on a neighbouring skeleton, are named in annex IV. It is, however, covered by the generic clause of that annex, stemming from the decisions of 22 May and 3 June 2024 (classification applicable from 3 June 2024): “any substance derived from the benzo[c]chromene nucleus”, non-, partially or fully hydrogenated on ring A, substituted notably “at position 1 by a hydroxyl function”, “at position 3 by an alkyl, alkenyl, alkynyl… chain”, “at position 6 by one or two alkyl groups” and “at position 9 by a ketone, alkyl, hydroxyalkyl or alkoxy function”, excluding cannabinol, cannabinolic acid, THCV and THCVA below 0.3 % and THCA below the legal content. AM-906, a hexahydrobenzo[c]chromene bearing a hydroxyl at position 1, a (Z)-hept-1-enyl chain at position 3, two methyls at position 6 and a hydroxymethyl at position 9, literally meets each of these points; this is a reading of the text and not a nominative decision of ANSM. The entry covering tetrahydrocannabinols, their esters, ethers and salts (annex III since the decision of 6 February 2026) does not concern it, the molecule being a hexahydrocannabinol.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

classical

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

AM-906 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Busch-Petersen et al., Journal of Medicinal Chemistry, 1996: β-11-hydroxyhexahydrocannabinol analogues with an unsaturated side chain (the cis-hept-1-enyl chain has the highest CB1 affinity, 0.89 nM, and the widest CB1/CB2 separation) (new tab)PMID 8809166
2. 2ChEMBL, compound CHEMBL441284 (AM-906): CB1 Ki 0.8 nM (rat brain microsomes) and CB2 Ki 9.5 nM (mouse spleen), [3H]CP-55940 displacement, document CHEMBL1129689 = J Med Chem 1996;39:3790 (new tab)
3. 3Zangani et al., Current Neuropharmacology, 2020: AM-906 picked up by a forum web crawler (14 November 2017 - 31 May 2019), absent from the UNODC (13 June 2019) and EMCDDA (1 April 2019) lists (new tab)PMID 32116194
4. 4UNODC, Recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists in seized materials (ST/NAR/48), 2013: AM-906 cited as an example of a classical cannabinoid (new tab)
5. 5ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026, Annex IV: clause « any substance derived from the benzo[c]chromene core » (decisions of 22 May and 3 June 2024); HU-210 and HU-243 named (new tab)
6. 6ANSM, ANSM adds new cannabinoids to the narcotics list, in force on 3 June 2024 (new tab)
7. 7INCB, Green List of psychotropic substances under international control, 35th edition, 2024 (Schedule II: AM-906 absent) (new tab)
8. 8PubChem, compound CID 10089808 (AM-906): identifiers, structure, CAS 180989-26-8 (new tab)

SMILES

CCCCC/C=C\C1=CC2=C([C@@H]3C[C@@H](CC[C@H]3C(O2)(C)C)CO)C(=C1)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.